Related Experiment Video
Updated: Jul 4, 2025
06:11
Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
Published on: February 9, 2022
5.6K
Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study
Louis-Philippe Boulet1, Carl Abbott2, Guy Brusselle3
1Quebec Heart and Lung Institute, Laval University, Québec, Québec, Canada.
The Journal of Allergy and Clinical Immunology. in Practice
|February 3, 2024
Summary
Lung function and patient age do not predict asthma treatment response to inhaled therapies. Adding umeclidinium to fluticasone furoate/vilanterol improved lung function, while doubling fluticasone furoate improved exacerbation rates.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Medicine
Background:
- Asthma treatment response varies based on type 2 inflammation markers.
- Personalized asthma management requires understanding how patient characteristics influence inhaled therapy response.
Purpose of the Study:
- To evaluate the predictive value of demographic and physiological variables on asthma treatment response.
- To assess the impact of adding umeclidinium (UMEC) or doubling fluticasone furoate (FF) dose in moderate to severe asthma patients.
Main Methods:
- Analysis of CAPTAIN trial data (NCT02924688).
- Investigated baseline lung function, bronchodilator reversibility, age, and age at asthma onset.
- Assessed treatment outcomes including FEV1, exacerbation rates, and asthma control (ACQ).
Main Results:
- Adding UMEC to FF/VI demonstrated greater improvements in trough FEV1 compared to doubling FF dose.
- Doubling FF dose showed numerically greater reductions in exacerbation rates versus adding UMEC.
- Both interventions generally improved Asthma Control Questionnaire scores regardless of baseline characteristics.
Conclusions:
- Lung function, bronchodilator reversibility, age, and age at asthma onset do not predict response to these inhaled asthma therapies.
- Findings contrast with previous observations regarding type 2 biomarkers in asthma treatment response.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
267
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
267
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K